Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.42 |
| ▸ | ADH1C | P00326 | 1/20 | 0.42 |
| ▸ | ADH1A | P07327 | 1/20 | 0.42 |
| ▸ | ADH7 | P40394 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16213011 | 0.82 | KDM4E (0.38) | KDM4ESMN1; SMN2CASP3POLBHCAR2 | |
| SCHEMBL5391143 | 0.78 | ADH1B (0.50) | ADH1BADH1CADH1AADH7 | |
| Hydrochloric Acid SCHEMBL5398165 | 0.76 | ADH1B (0.48) | ADH1BADH1CADH1AADH7 | |
| SCHEMBL748621 | 0.76 | POLB (0.41) | KDM4ESMN1; SMN2CASP3POLBHCAR2 | |
| SCHEMBL22658219 | 0.76 | POLB (0.37) | KDM4ESMN1; SMN2CASP3POLBHCAR2 | |
| SCHEMBL15301629 | 0.76 | KDM4E (0.41) | KDM4ESMN1; SMN2POLBHCAR2MAPT | |
| SCHEMBL30639769 | 0.75 | KDM4E (0.39) | KDM4ESMN1; SMN2POLBHCAR2MAPT | |
| SCHEMBL27784845 | 0.75 | KDM4E (0.43) | KDM4ESMN1; SMN2POLBHCAR2MEN1 | |
| SCHEMBL1750523 | 0.75 | KDM4E (0.39) | KDM4ESMN1; SMN2POLBHCAR2MAPT | |
| SCHEMBL5315899 | 0.74 | ADH1B (0.50) | ADH1BADH1CADH1AADH7HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| EP-3653618-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2020-05-20 | — | — | EP | disclosed |
| EP-2755963-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-10-30 | — | — | EP | disclosed |
| US-9745289-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| US-20160108026-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-21 | — | — | US | disclosed |
| US-9260408-B2 | Dihydroquinoline-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20140275175-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| EP-2755963-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-23 | — | — | EP | disclosed |
| US-8778972-B2 | 5-pyridin-3-yl-1, 3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1 | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-20130072679-A1 | DIHYDROQUINOLINE-2-ONE DERIVATIVES | CINCOR PHARMA, INC. | 2013-03-21 | — | — | US | disclosed |
| WO-2013037779-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| WO-2010130794-A1 | 5-PYRIDIN-3-YL-1,3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | NOVARTIS AG (CH) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275175-A1 | ORGANIC COMPOUNDS | CYP11B2, CYP11B1, SLCO1B1 | ADH1B 375/4885ADH1C 903/4885ADH1A 806/4885 |
| US-20160108026-A1 | ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, HSD11B1 | ADH1B 113/4885ADH1C 98/4885ADH1A 130/4885 |
| US-20130072679-A1 | DIHYDROQUINOLINE-2-ONE DERIVATIVES | CYP11B1, CYP11B2, HSD11B1 | ADH1B 75/4885ADH1C 110/4885ADH1A 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.